Entinostat (MS-275)

Catalog No.S1053

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Entinostat (MS-275) Chemical Structure

Entinostat (MS-275) Chemical Structure
Molecular Weight: 376.41

Validation & Quality Control

Cited by 61 publications:

14 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Entinostat (MS-275) is available in the following compound libraries:

HDAC Inhibitors with Unique Features

Product Information

  • Compare HDAC Inhibitors
    Compare HDAC Products
  • Research Area

Product Description

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
IC50 0.51 μM 1.7 μM
In vitro MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SCC-3NYjldGQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TEb2lEPTB;MD6wOlEh|ryPMWrTRW5ITVJ?
ALL-POMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDoTWM2OD1yLkC2N|U2KM7:TR?=NUHaTFVmW0GQR1XS
697MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjScYhKSzVyPUCuNFk6PzZizszNNF\6dXFUSU6JRWK=
NCI-H748NVTrbZhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HEZWlEPTB;MD6xNFM{PCEQvF2=M{D5O3NCVkeHUh?=
NKM-1MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGKxelJKSzVyPUCuNVA6OTJizszNMnrXV2FPT0WU
ES1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzpZlEzUUN3ME2wMlEyOjV3IN88US=>NHTVeWhUSU6JRWK=
NCI-H1963MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELlPHNKSzVyPUCuNVE2PzlizszNNX\1V5NoW0GQR1XS
NCI-H1417NVvvZ|BRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;Od2lEPTB;MD6xNlk4PCEQvF2=MlnRV2FPT0WU
NEC8MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWe2WJNsUUN3ME2wMlE{PTJ5IN88US=>MnzNV2FPT0WU
CRO-AP2NUKxVVVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTBwMU[4PFkh|ryPM2H3SHNCVkeHUh?=
A3-KAWNEXse5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPuR20{UUN3ME2wMlE4PjJ5IN88US=>M4DVUXNCVkeHUh?=
SF539NGX3OFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTBwMUm1PVMh|ryPM4PEcHNCVkeHUh?=
NOS-1M{GyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fNSWlEPTB;MD6xPVYyQSEQvF2=MXTTRW5ITVJ?
NTERA-S-cl-D1NUPvNVFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2flPGlEPTB;MD6yNFEyOyEQvF2=MkPYV2FPT0WU
COR-L88M4PJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTBwMkK5OVkh|ryPMXfTRW5ITVJ?
EM-2M2jxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnwbGhiUUN3ME2wMlI1ODd7IN88US=>MUfTRW5ITVJ?
KARPAS-45NXPZfIZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHnZfpZKSzVyPUCuNlc5OzNizszNNIXDeWtUSU6JRWK=
DSH1NXr1ZY9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4SwTGlEPTB;MD6yPFcxQCEQvF2=NHHKT4VUSU6JRWK=
HT-144Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\NcmlEPTB;MD6zNFI2PiEQvF2=NXrtVnNDW0GQR1XS
ATN-1MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M36yd2lEPTB;MD6zNFU4PiEQvF2=MlS5V2FPT0WU
HELNVy1UoIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DEN2lEPTB;MD6zNVM1QCEQvF2=MUXTRW5ITVJ?
NB12NGLudWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljtTWM2OD1yLkOxO|U3KM7:TR?=NFXYNGVUSU6JRWK=
LU-139MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzqTWM2OD1yLkOzOVEh|ryPM1LLcnNCVkeHUh?=
J-RT3-T3-5M17wNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHQdlBmUUN3ME2wMlM{PzF4IN88US=>MULTRW5ITVJ?
MOLT-13MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX35OXA6UUN3ME2wMlM{QDFizszNM1nldnNCVkeHUh?=
SRMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVO4Zmx6UUN3ME2wMlM1OjZzIN88US=>M4Kwe3NCVkeHUh?=
CMKNIH1ZlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTBwM{W3Nlch|ryPMoDMV2FPT0WU
ES8NHe4ZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7yRldHUUN3ME2wMlM3ODJ{IN88US=>NUnJeZd{W0GQR1XS
LB647-SCLCMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjQ[ZdKSzVyPUCuN|Y4OyEQvF2=M4W2OnNCVkeHUh?=
TE-8NFTIRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\LTWM2OD1yLkO2PVM2KM7:TR?=NUe2SI5KW0GQR1XS
BV-173Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmPXTWM2OD1yLkO3NVIyKM7:TR?=M1q3WHNCVkeHUh?=
DELMoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjCTY8zUUN3ME2wMlM4PDh5IN88US=>NHnJTmFUSU6JRWK=
ARH-77NXrwT5NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3z6c2lEPTB;MD6zPFE6OyEQvF2=M2XnTXNCVkeHUh?=
NCCITNFv3O|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWqzZZlxUUN3ME2wMlM5PjR7IN88US=>M4PuO3NCVkeHUh?=
RPMI-8402MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjFZVFKSzVyPUCuN|g4ODFizszNNF3FdllUSU6JRWK=
MONO-MAC-6NFPLS|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfRSJhxUUN3ME2wMlM5Pzd4IN88US=>NXvKU2oyW0GQR1XS
SK-MM-2NX[zUZdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTBwM{m4Olgh|ryPMUTTRW5ITVJ?
CHP-126MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;z[oYzUUN3ME2wMlQxOjNzIN88US=>NUPIR2NpW0GQR1XS
A101DNGXqcZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTBwNECzJO69VQ>?NXLmSFFQW0GQR1XS
SCHMoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYH0SHVFUUN3ME2wMlQxOzR{IN88US=>NHv4OllUSU6JRWK=
NMC-G1M3H1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnHWTWM2OD1yLkSwN|Y4KM7:TR?=MYjTRW5ITVJ?
NCI-H209M4Hq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTBwNEC2NVMh|ryPM4\tOXNCVkeHUh?=
MOLT-16MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPGNJdKSzVyPUCuOFExOTdizszNNIHHeJFUSU6JRWK=
RPMI-6666NYK4TppuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkewTWM2OD1yLkSxNVIh|ryPMoPZV2FPT0WU
OPM-2MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTBwNEG1NVMh|ryPM3O1TXNCVkeHUh?=
MRK-nu-1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHfyO5pKSzVyPUCuOFMyPTNizszNMUjTRW5ITVJ?
BC-1MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;CTWM2OD1yLkSzOFA{KM7:TR?=NXr1OXo3W0GQR1XS
MHH-NB-11M3zhW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPGRoJKSzVyPUCuOFM1PTNizszNNILISG5USU6JRWK=
Ramos-2G6-4C10MlnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DkZWlEPTB;MD60N|g6PyEQvF2=M{LJW3NCVkeHUh?=
LS-513MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHwTWM2OD1yLkS0OVAyKM7:TR?=Mlm4V2FPT0WU
K5NX;ZUY1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nLXmlEPTB;MD60O|AzPSEQvF2=MnzMV2FPT0WU
HOP-62NYG5O2VrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnaSFFKSzVyPUCuOFg{PThizszNNGLzN2FUSU6JRWK=
NCI-H187M1SzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrVT21KSzVyPUCuOFkzOjdizszNMXLTRW5ITVJ?
BE-13M2K3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zLcGlEPTB;MD60PVY3OSEQvF2=MV\TRW5ITVJ?
HC-1NGO1WZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\mTWM2OD1yLkWwOFc{KM7:TR?=NIn5eYNUSU6JRWK=
ACNM13wcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmXlTWM2OD1yLkWxNFI5KM7:TR?=MoLBV2FPT0WU
HCC1599MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3vmc2lEPTB;MD61NVU4KM7:TR?=NXTwZlltW0GQR1XS
MV-4-11NF;t[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWntN|NyUUN3ME2wMlU{ODRzIN88US=>NYe2RlhbW0GQR1XS
LC-2-adM2LBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTBwNUO2OlMh|ryPNInmd5BUSU6JRWK=
HL-60MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnuTWM2OD1yLkW0NlYyKM7:TR?=NED0SppUSU6JRWK=
NB17M4G0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{O1VGlEPTB;MD61OFM5KM7:TR?=MV;TRW5ITVJ?
TE-1NEnyUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TMTmlEPTB;MD61OVMxPiEQvF2=MVvTRW5ITVJ?
NCI-H524NGrkWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rYcWlEPTB;MD61OVQxOSEQvF2=MmjYV2FPT0WU
MZ7-melMny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXzR|lKSzVyPUCuOVYyODVizszNNV;1SnE5W0GQR1XS
L-363NX7CN|htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHQTWM2OD1yLkW2OlU4KM7:TR?=MV\TRW5ITVJ?
BL-41NEn5bVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTBwNU[4PFkh|ryPMWDTRW5ITVJ?
LU-134-ANGP6fHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTBwNUewO|Mh|ryPMoTDV2FPT0WU
SIG-M5NIHw[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPjTWM2OD1yLkW3PFQ5KM7:TR?=MkjyV2FPT0WU
ONS-76Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTBwNUiyOFIh|ryPMlL3V2FPT0WU
KARPAS-299M1LKe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHnz[|ZKSzVyPUCuOVg2ODRizszNNVzibG1ZW0GQR1XS
DU-4475M4LOOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTBwNUi3NFMh|ryPNYf6TYM5W0GQR1XS
NB69MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nmO2lEPTB;MD61PVgzPSEQvF2=NWnKVlE3W0GQR1XS
MHH-PREB-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2fpdGlEPTB;MD62NFcyQSEQvF2=M1rBOHNCVkeHUh?=
LU-165NULFd5NST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXJe|NIUUN3ME2wMlYyQDF{IN88US=>NHXiTWtUSU6JRWK=
LOUCYNFPxRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLFTWM2OD1yLk[zN|Y1KM7:TR?=MUDTRW5ITVJ?
NCI-H526MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVfkOlZsUUN3ME2wMlY{PTRzIN88US=>NXLnO29wW0GQR1XS
KE-37NVTqXJpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1z3eWlEPTB;MD62OFI4PiEQvF2=M{\4PXNCVkeHUh?=
NALM-6NGH3OIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2ftcGlEPTB;MD62OFg3KM7:TR?=M4qxSnNCVkeHUh?=
CW-2NF;UVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXXxWWp[UUN3ME2wMlY2Pzl2IN88US=>NVWwN4ZQW0GQR1XS
SU-DHL-1MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LJTGlEPTB;MD62OVk1PyEQvF2=NYPDUIlrW0GQR1XS
NB13M2Cybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PuOGlEPTB;MD62OlgyPyEQvF2=M2GxVHNCVkeHUh?=
QIMR-WILNXzR[GhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnt[VczUUN3ME2wMlY5OzR|IN88US=>MU\TRW5ITVJ?
ECC12NWLLS5d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1v0eGlEPTB;MD63NFA5PiEQvF2=NIDIdZRUSU6JRWK=
KALS-1M3O2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3DTWM2OD1yLkewOFkzKM7:TR?=NVX6dppnW0GQR1XS
COR-L279M3vIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4HPRWlEPTB;MD63NFk6PiEQvF2=MkfFV2FPT0WU
NB14MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3DV5pKSzVyPUCuO|I3OTdizszNNEm1PZBUSU6JRWK=
CCRF-CEMMkjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDETWM2OD1yLke0OlYyKM7:TR?=MlT2V2FPT0WU
SW954NYTkTnlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LGRmlEPTB;MD63OVk6QSEQvF2=MVzTRW5ITVJ?
IST-SL1M3nSVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTBwN{ezOFgh|ryPMX\TRW5ITVJ?
LAMA-84NFv5clJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\ZZ41WUUN3ME2wMlc4PTZ5IN88US=>MoLOV2FPT0WU
DaudiNX[0RYZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrI[ohKSzVyPUCuO|c3QDFizszNM3\3eHNCVkeHUh?=
BC-3MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVXJR|UxRTBwN{izNFgh|ryPNY\k[VVVW0GQR1XS
HCC2998NUGwSJdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1z1e2lEPTB;MD63PFM3KM7:TR?=NIDQ[YZUSU6JRWK=
NCI-H69NILBdlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLFSphZUUN3ME2wMlgxOTR5IN88US=>NIPiPIFUSU6JRWK=
CPC-NM{\STmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUSyXVNQUUN3ME2wMlgxPTJ2IN88US=>M2TYPHNCVkeHUh?=
NOMO-1NVfib4o6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnPcoZKSzVyPUCuPFExQDRizszNNGLUfmZUSU6JRWK=
CESSNXT5WXVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPqTG9KSzVyPUCuPFEyQTdizszNMlfrV2FPT0WU
LC4-1NF2wR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGWxb25KSzVyPUCuPFQxODdizszNMXzTRW5ITVJ?
BL-70MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkGyTWM2OD1yLki1O|AzKM7:TR?=NFzKV2VUSU6JRWK=
ES4NX;LfGFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnSTWM2OD1yLki1PFY5KM7:TR?=NVeySGFpW0GQR1XS
HCE-TM4DY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXDbGZKSzVyPUCuPFcyPzFizszNMYDTRW5ITVJ?
JARMnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnm1TWM2OD1yLki3PFI4KM7:TR?=NGXSPIJUSU6JRWK=
ST486MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrlTWM2OD1yLki3PVE4KM7:TR?=M1vjNXNCVkeHUh?=
KS-1MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTBwOEiwPVYh|ryPMVLTRW5ITVJ?
GDM-1M{W5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzhbFJxUUN3ME2wMlg5Pjh5IN88US=>NHLTTWFUSU6JRWK=
EHEBNIKyTXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTBwOUK1PFUh|ryPMUXTRW5ITVJ?
LB2518-MELNYCzVZVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTBwOUOyPFQh|ryPM3\lR3NCVkeHUh?=
GOTOMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIL4RndKSzVyPUCuPVUxPzZizszNM{H1bXNCVkeHUh?=
LXF-289NFOxVY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTBwOUW5NFEh|ryPMnm2V2FPT0WU
ES6MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml2wTWM2OD1yLkm2OFM4KM7:TR?=MmfuV2FPT0WU
OS-RC-2MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;NXmlEPTB;MD65Olg{KM7:TR?=MW\TRW5ITVJ?
DMS-153MlzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfGdHhKSzVyPUCuPVc1PjlizszNMX7TRW5ITVJ?
SK-PN-DWNWrQUHlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HoU2lEPTB;MD65O|g{OSEQvF2=Ml7QV2FPT0WU
HHMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTBwOUi5OVkh|ryPNFjRfI5USU6JRWK=
SH-4Ml3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXWTWM2OD1zLkCyOFEh|ryPNIjzd2dUSU6JRWK=
MOLT-4MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LENGlEPTB;MT6wN|Q2PCEQvF2=MoHuV2FPT0WU
TGWNFjNbmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfNTWM2OD1zLkC3Olc2KM7:TR?=MlnJV2FPT0WU
L-540NXKwS4ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEfO[VRKSzVyPUGuNVA3ODRizszNNGHvNZlUSU6JRWK=
PF-382MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3H5SGlEPTB;MT6xNVUyOyEQvF2=M1:4VnNCVkeHUh?=
LC-1FMl7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDBZ4xKSzVyPUGuNVIxODdizszNMULTRW5ITVJ?
OVCAR-4MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF75OlJKSzVyPUGuNVMyPjVizszNMnvXV2FPT0WU
A4-FukNYnkV3VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTFwMUWzOlQh|ryPM4qzPHNCVkeHUh?=
HCC2218MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHEeGNyUUN3ME2xMlE3PjRzIN88US=>NXjVV|dnW0GQR1XS
HAL-01MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4rx[GlEPTB;MT6xOlk1OyEQvF2=MmjvV2FPT0WU
IST-MEL1NHuw[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHZ[mdKSzVyPUGuNVc3PTlizszNMYDTRW5ITVJ?
NCI-H719NXH4dXpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTFwMUe4PVgh|ryPNXP1XYVzW0GQR1XS
EVSA-TMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHkTWM2OD1zLkG4NVE1KM7:TR?=NYjZNGtRW0GQR1XS
SK-NEP-1MmHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTFwMkCyOlYh|ryPM{LzV3NCVkeHUh?=
OCUB-MMlLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTFwMkG0PFkh|ryPNXHycGNSW0GQR1XS
MEG-01MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1L5WmlEPTB;MT6yNlEyQCEQvF2=M2O1b3NCVkeHUh?=
no-10MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTFwMkOxNVIh|ryPMUfTRW5ITVJ?
MHH-CALL-2M1LOWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXPV5VUUUN3ME2xMlI1PzJzIN88US=>MYnTRW5ITVJ?
SK-N-DZMkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTFwMkS3O|Yh|ryPM4[5WHNCVkeHUh?=
SCLC-21HM3;EWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHHTWM2OD1zLkK2OFc5KM7:TR?=MnvhV2FPT0WU
CTV-1M2\X[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\jUnhKSzVyPUGuNlc1OjVizszNM{H2fnNCVkeHUh?=
NB1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{jsOGlEPTB;MT6yO|c{OiEQvF2=NHXRfm1USU6JRWK=
NCI-H64NI\RXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDWdpI3UUN3ME2xMlI5PDZ{IN88US=>NWD4U2VYW0GQR1XS
MDA-MB-134-VINI\TUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXKTWM2OD1zLkK4OVc4KM7:TR?=M3jtdHNCVkeHUh?=
LB2241-RCCMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTFwMki2OlMh|ryPMV\TRW5ITVJ?
8-MG-BANFjHXodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTFwMki4OlYh|ryPNUn4bJh5W0GQR1XS
LP-1NU[4fFFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1P4PGlEPTB;MT6yPVk1PyEQvF2=NF\5N3JUSU6JRWK=
LS-411NNXfqNoE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWWzNGR5UUN3ME2xMlMxQTl6IN88US=>MV;TRW5ITVJ?
CAL-148NHr2R2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTFwM{K1OFIh|ryPM1LUfnNCVkeHUh?=
NCI-H2171MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVz0N4tsUUN3ME2xMlM1PTB{IN88US=>MYDTRW5ITVJ?
JiyoyeP-2003MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\2Z2pKSzVyPUGuN|U{QSEQvF2=Mn7EV2FPT0WU
NCI-H2107MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTFwM{W4PFMh|ryPMnTBV2FPT0WU
BB30-HNCMoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13UWWlEPTB;MT6zPFk4QCEQvF2=MWLTRW5ITVJ?
K-562NXPJeW5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\4TWM2OD1zLkO5NlE6KM7:TR?=MYTTRW5ITVJ?
PSN1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPZfY93UUN3ME2xMlQzOjh5IN88US=>MVnTRW5ITVJ?
HCC2157NG\6SIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWX6UJF7UUN3ME2xMlQzPjlzIN88US=>NU\jWYdkW0GQR1XS
SBC-1M1nzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1PUUWlEPTB;MT60Nlc1OSEQvF2=NFv2dGtUSU6JRWK=
MC116MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLvTWM2OD1zLkSzOlE2KM7:TR?=NWXvOYUyW0GQR1XS
KARPAS-422M4HYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjhZ2hKSzVyPUGuOFU{PThizszNNG\rbYRUSU6JRWK=
LB996-RCCMnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\RTWM2OD1zLkS3NVA{KM7:TR?=NXfWOllsW0GQR1XS
MSTO-211HNWP4S|ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH\5SY5KSzVyPUGuOFc6QDdizszNMUDTRW5ITVJ?
BT-474NWDyTFNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\1[IVKSzVyPUGuOVE4PjRizszNMUnTRW5ITVJ?
A388MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTFwNUG5OFUh|ryPNYXGWYZFW0GQR1XS
SJSA-1M4i1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\WNGp[UUN3ME2xMlUzOjZizszNMkTHV2FPT0WU
COLO-829M{HuZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17veWlEPTB;MT61N|U3PCEQvF2=NFHMVHpUSU6JRWK=
KM-H2M3;j[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPHNHJEUUN3ME2xMlU3PjdizszNMoKzV2FPT0WU
GR-STMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHudm1[UUN3ME2xMlU3QDJizszNNVzNR5lYW0GQR1XS
RPMI-8866MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXrTWM2OD1zLk[wNVQ1KM7:TR?=MnPjV2FPT0WU
KG-1M1XDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3USndqUUN3ME2xMlYyQTBzIN88US=>NXzLelRbW0GQR1XS
NCI-H82MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjVcVJKSzVyPUGuOlM1ODZizszNM{Wwd3NCVkeHUh?=
LB1047-RCCM32yb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTFwNkO0OVkh|ryPM2jQZ3NCVkeHUh?=
KM12NWnhd5p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXBTWM2OD1zLk[0O{DPxE1?MlHlV2FPT0WU
NB5MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDCNGZKSzVyPUGuOlU3PzdizszNNGfTbXNUSU6JRWK=
HDLM-2MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTFwNkiyPFEh|ryPMYrTRW5ITVJ?
KU812M2HDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\lUmlEPTB;MT62PVYxPSEQvF2=Mnj4V2FPT0WU
DBMn;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PzWmlEPTB;MT63NFM2OyEQvF2=NHvlWYdUSU6JRWK=
HD-MY-ZNFS4fopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDLS5BRUUN3ME2xMlc2OjN2IN88US=>MlHsV2FPT0WU
KURAMOCHINWDqUIdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfoXINYUUN3ME2xMlc4OjB5IN88US=>M2jjXXNCVkeHUh?=
ETK-1NXnsc|R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{K2RmlEPTB;MT63PFg4QSEQvF2=NVPPTGJjW0GQR1XS
SK-UT-1MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTFwN{mzPFgh|ryPM2LsdXNCVkeHUh?=
HUTU-80Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTFwN{m1NFgh|ryPMVrTRW5ITVJ?
ES7Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDNVWRKSzVyPUGuPFA{ODJizszNNELjRmlUSU6JRWK=
SW872MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HjVGlEPTB;MT64NVM6PSEQvF2=NXfpT5l6W0GQR1XS
TK10MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NES1T3ZKSzVyPUGuPFMyODhizszNNFrub41USU6JRWK=
LB831-BLCMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfVVWRKSzVyPUGuPFM2PjNizszNNUCx[HR[W0GQR1XS
TE-9NVfSZZdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTFwOES0NlIh|ryPMojPV2FPT0WU
MLMAMoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDNVFZtUUN3ME2xMlg5OjN2IN88US=>NXnnWIREW0GQR1XS
D-542MGMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXofYVKSzVyPUGuPFk{PzNizszNNHvwdHdUSU6JRWK=
EW-16NIPJZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDTXJhtUUN3ME2xMlkzPzJizszNNVvCSpNPW0GQR1XS
LOXIMVIM{i0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TMfWlEPTB;MT65N|I5KM7:TR?=MmixV2FPT0WU
GB-1NGTSV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2H3UWlEPTB;MT65N|g3PiEQvF2=NXT6emx[W0GQR1XS
IST-SL2MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mni5TWM2OD1{LkCwNlYzKM7:TR?=NH;LfWtUSU6JRWK=
LAN-6M{nnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4S2RWlEPTB;Mj6wNVk3PiEQvF2=M2XtT3NCVkeHUh?=
NCI-H510AMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVv5NGhIUUN3ME2yMlA1PTB{IN88US=>MYrTRW5ITVJ?
NCI-H1092MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVTwOIVTUUN3ME2yMlA2OTJ2IN88US=>MYDTRW5ITVJ?
HTNYr2VZNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPQe2VKSzVyPUKuNVA1PTRizszNMoPHV2FPT0WU
RL95-2MnPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLleZhKSzVyPUKuNVE1QDJizszNM{fEdnNCVkeHUh?=
NCI-H1355M1nhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HDRmlEPTB;Mj6xNVc6OiEQvF2=M4nmdXNCVkeHUh?=
NCI-H720MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVr4UWJ3UUN3ME2yMlE3QDd|IN88US=>MX;TRW5ITVJ?
NCI-H1522MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7BNpYzUUN3ME2yMlIyPzJ|IN88US=>M1j6d3NCVkeHUh?=
LB373-MEL-DNVLBUJVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{[yWWlEPTB;Mj6yOlkxOiEQvF2=NVS4S4VQW0GQR1XS
DG-75NGXSSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTJwMkexOFgh|ryPMoroV2FPT0WU
ML-2M1XWemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vLXGlEPTB;Mj6zNlg2PSEQvF2=M{TZ[3NCVkeHUh?=
SF126NGLLWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HtemlEPTB;Mj6zN|A6PCEQvF2=NH;OOFBUSU6JRWK=
MPP-89NInGbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTJwM{OxOFUh|ryPM1XlR3NCVkeHUh?=
NCI-H345NH\Sc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\5NYJKSzVyPUKuN|MzPzdizszNMXjTRW5ITVJ?
LS-123MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTJwM{S5N|Yh|ryPMV3TRW5ITVJ?
NB10NXHq[oFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\WWG5KSzVyPUKuOFExQTJizszNNFXUbolUSU6JRWK=
CGTH-W-1NI\nbYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVK3bZVoUUN3ME2yMlQzOjZ5IN88US=>M2HiXnNCVkeHUh?=
CP66-MELNEHqWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH34V|RKSzVyPUKuOFc4PyEQvF2=MlflV2FPT0WU
L-428NVziVW1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M330cWlEPTB;Mj60PFUzOSEQvF2=MlTIV2FPT0WU
DMS-79MlPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2i0dmlEPTB;Mj61OFExOyEQvF2=MnOwV2FPT0WU
NCI-H1882M4jUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nIcGlEPTB;Mj62O|U3OiEQvF2=NYf4OIhGW0GQR1XS
KGNMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fXfmlEPTB;Mj63Olg4PiEQvF2=NF7qUXNUSU6JRWK=
EW-1Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHK4SlNKSzVyPUKuO|cxQDNizszNNIHLZ4dUSU6JRWK=
U-266M1PHWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnPXmU4UUN3ME2yMlg1QDJ|IN88US=>NG\RSINUSU6JRWK=
COLO-320-HSRNF;KPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\GPGFKSzVyPUKuPFU3PDFizszNMWLTRW5ITVJ?
KMOE-2NXfwXJZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTJwOEe3NVEh|ryPNHLYXYpUSU6JRWK=
BB49-HNCNUHVSFd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\XXWJKSzVyPUKuPVI1QCEQvF2=MoPyV2FPT0WU
GI-1NFz2bpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojMTWM2OD1{LkmyPVU4KM7:TR?=M2XFfHNCVkeHUh?=
NCI-H1304NGD5NWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTNwMEC1NVEh|ryPNGLhbFBUSU6JRWK=
NCI-H2227NHvp[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnCOZVKSzVyPUOuNFIxPzlizszNMmryV2FPT0WU
U-87-MGM3jYXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnHUTWM2OD1|LkCzOVE{KM7:TR?=MXnTRW5ITVJ?
NCI-H747NFfCbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkPtTWM2OD1|LkC1NlA3KM7:TR?=NUDPV4RNW0GQR1XS
CTB-1M3e2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13GUmlEPTB;Mz6wOVM4PiEQvF2=M1:xWnNCVkeHUh?=
RPMI-8226MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;sPYJsUUN3ME2zMlE1Ozd6IN88US=>NHntW5dUSU6JRWK=
NCI-H2141MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\zVXVKSzVyPUOuNVY2PjZizszNM{XZ[nNCVkeHUh?=
IST-MES1NG\Pc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWnmWWs3UUN3ME2zMlE5Ojd7IN88US=>MUPTRW5ITVJ?
TE-5MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofRTWM2OD1|LkKxN|QzKM7:TR?=MofoV2FPT0WU
UACC-257NY\CdJNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{DRRWlEPTB;Mz60N|Y2QSEQvF2=MoPmV2FPT0WU
SK-N-FIMoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\nZmlEPTB;Mz60OVIzPyEQvF2=MVTTRW5ITVJ?
MFH-inoMl\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWe4PYhPUUN3ME2zMlQ3PTh7IN88US=>Ml;xV2FPT0WU
SF268NV;6cJhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX[5bppuUUN3ME2zMlQ5OTd2IN88US=>MY\TRW5ITVJ?
TE-12NV\W[4dUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfTbYpKSzVyPUOuOVE3QTlizszNNVO4Rmt{W0GQR1XS
NB6NFfXXIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1rucWlEPTB;Mz61OVU3OyEQvF2=MoTUV2FPT0WU
DJM-1NXfvZWhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHr1UodKSzVyPUOuOVk5QTlizszNNInMPW1USU6JRWK=
MZ1-PCMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHiZoF[UUN3ME2zMlYyPjJ2IN88US=>MXPTRW5ITVJ?
OCI-AML2NYfIclExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M134eGlEPTB;Mz62NlY4OSEQvF2=NXfpeYJyW0GQR1XS
NCI-H1155MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlvTTWM2OD1|LkewPVQ4KM7:TR?=NHjNVI1USU6JRWK=
RKONVi2ZlNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI[0cnFKSzVyPUOuO|cyQDlizszNMmPqV2FPT0WU
ECC4M2\TVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITVW3JKSzVyPUOuPVcyQTVizszNNE[0b41USU6JRWK=
BB65-RCCMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTNwOUe1OFch|ryPM4HSVXNCVkeHUh?=
EB-3NVK4PWV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTNwOUm2N|Mh|ryPMnLDV2FPT0WU
SHP-77NVHvUYFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7kNVVKSzVyPUSuNFA2OjRizszNMWXTRW5ITVJ?
NCI-H2196NILHZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rp[WlEPTB;ND6wOVYzPSEQvF2=NGj5TFZUSU6JRWK=
GI-ME-NMki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTRwME[zPVkh|ryPMV;TRW5ITVJ?
MN-60NXnzN3l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGX0WFdKSzVyPUSuNVA5PyEQvF2=NIfkfpJUSU6JRWK=
NCI-H1694M{fKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTRwMUO0NFUh|ryPNFXUdFlUSU6JRWK=
LU-65MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\xb4pKSzVyPUSuNVU{OzJizszNMl\WV2FPT0WU
NCI-H1436MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTRwMUizN|Mh|ryPMm\4V2FPT0WU
KINGS-1M{nLUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPGfIxKSzVyPUSuN|E1OzJizszNNXrofYJOW0GQR1XS
GT3TKBNWj1T3ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2q2SmlEPTB;ND6zN|I3QCEQvF2=NELZdJBUSU6JRWK=
BeckerMmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTRwM{ezNVIh|ryPMnHTV2FPT0WU
HCC1187MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTRwOEm2OVch|ryPNWLlUJFNW0GQR1XS
D-502MGNHPkNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jKUmlEPTB;NT6wNFQyPiEQvF2=M3nCNXNCVkeHUh?=
VA-ES-BJNX\TWYw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvHRo9KSzVyPUWuNVM4PzhizszNNYTieXFtW0GQR1XS
NB7MlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPGfJdKSzVyPUWuNVQyOTJizszNNUPSTm02W0GQR1XS
SW962NVrzbFB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTVwM{i4NVQh|ryPMVXTRW5ITVJ?
no-11M4Xv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLyTWM2OD13Lke2N|Q{KM7:TR?=MV;TRW5ITVJ?
KNS-81-FDMl;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTSSmlKSzVyPUWuPVA3QTRizszNNV7SOI9{W0GQR1XS
COLO-684NWHCbVV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTVwOUm0PVQh|ryPM2jCTXNCVkeHUh?=
D-263MGNX;yOYFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFG3W2JKSzVyPU[uNFg5QTVizszNMkPSV2FPT0WU
EW-24MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTZwMki1NUDPxE1?M3qze3NCVkeHUh?=
TE-10M3TMbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTZwNEK2NlMh|ryPMXjTRW5ITVJ?
EKVXMm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\menFKSzVyPU[uOFY{OjFizszNNEfJUZJUSU6JRWK=
NCI-H1648MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHrNbWtKSzVyPU[uOlc2PTdizszNM3vHXHNCVkeHUh?=
LB771-HNCMlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfpTWM2OD14LkmyN|AyKM7:TR?=M1vPNHNCVkeHUh?=
SK-MEL-1MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRThwMUOxOlYh|ryPM4fq[3NCVkeHUh?=
COLO-668MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLnTWM2OD16LkK3O|g3KM7:TR?=MmT6V2FPT0WU
EW-12MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3ETWM2OD16LkSwPFA{KM7:TR?=M1jubXNCVkeHUh?=
A253MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml35TWM2OD16Lki0OlYyKM7:TR?=NVO4XmZ6W0GQR1XS
NCI-H2126M3PpOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1LYSGlEPTB;OD64PVMyQSEQvF2=Mlq3V2FPT0WU
Calu-6Mmq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jVbWlEPTB;OD65PVA1OiEQvF2=NVXjW3hHW0GQR1XS
NCI-H23MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLETWM2OD17LkG3O|Q3KM7:TR?=MmH3V2FPT0WU
WSU-NHLNYPySnJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHJVIpKSzVyPUmuO|c1PzhizszNNF36[HhUSU6JRWK=
MMAC-SFM3\adGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnr0TWM2OD17Lkm3PVA1KM7:TR?=MVHTRW5ITVJ?
SK-LMS-1M3i1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTFyLkK4N|Qh|ryPM3\seXNCVkeHUh?=
GCIYNF3SSXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;aXWlEPTB;MUCuOVkzPCEQvF2=Ml:2V2FPT0WU
TE-15NHn6blhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfI[HJWUUN3ME2xNU43ODB2IN88US=>MWLTRW5ITVJ?
EoL-1-cellM3Lj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTFzLke2PFIh|ryPMkTLV2FPT0WU
NCI-H2081MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWm1PFkxUUN3ME2xNU44Pzh4IN88US=>M1HDc3NCVkeHUh?=
EW-3M1ztUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;VcIJKSzVyPUGyMlI1PjNizszNMWrTRW5ITVJ?
CAS-1M1vIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXwRmhTUUN3ME2xNk4{PjNzIN88US=>MYrTRW5ITVJ?
C2BBe1MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;SfmlEPTB;MUKuOlE{OSEQvF2=NGDxNFZUSU6JRWK=
D-247MGNVzMb|ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIPQOopKSzVyPUGyMlc6PTJizszNM2fjWHNCVkeHUh?=
NCI-SNU-5NIDjeXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTF{LkiwNVMh|ryPMV;TRW5ITVJ?
LS-1034NX7zW5hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXzjZ3ltUUN3ME2xOE4{QTd3IN88US=>M3nadnNCVkeHUh?=
EW-18NI\NSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVLIN3V5UUN3ME2xOE41PDhizszNMX;TRW5ITVJ?
RajiMoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTF2LkWwOFkh|ryPMnHZV2FPT0WU
D-283MEDMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGD4N4hKSzVyPUG0MlYzPzFizszNNGToU2JUSU6JRWK=
MZ2-MELM132[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXjTWM2OD1zND65Olk3KM7:TR?=NF;M[4VUSU6JRWK=
NCI-SNU-16NFnhTIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHTTWM2OD1zNT60OlM{KM7:TR?=MoHzV2FPT0WU
P30-OHKNEDHeXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTF5Lke4N|Eh|ryPNVLZT5BtW0GQR1XS
RXF393M3LRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDETWM2OD1zOT6wNVg3KM7:TR?=NXjBN3h6W0GQR1XS
NCI-H1395M4flSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIK2d|FKSzVyPUKwMlY4ODNizszNMYTTRW5ITVJ?
U-698-MMnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfySIdKSzVyPUKwMlcxPzVizszNNGfQV3FUSU6JRWK=
NCI-SNU-1M2D1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljQTWM2OD1{MD63NlI{KM7:TR?=NV7ufnpJW0GQR1XS
SW684M3f4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTJzLkG3NVYh|ryPNU\WTWl1W0GQR1XS
NCI-H716NIDJcXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{D1SmlEPTB;MkGuN|E2PCEQvF2=Mo\5V2FPT0WU
JVM-2MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDCT5JKSzVyPUKxMlQyOzNizszNM4rzUXNCVkeHUh?=
NCI-H1581NYrvSVZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PjNGlEPTB;MkKuOFE1QCEQvF2=NXzqeZRNW0GQR1XS
CA46MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVfzenF6UUN3ME2zNU43QTN4IN88US=>M2P2THNCVkeHUh?=
SNB75MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfmcZZKSzVyPUOzMlY2ODNizszNNYfqT4ZGW0GQR1XS
KNS-42NEPVfGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4PlOWlEPTB;M{WuPVYzPCEQvF2=NYnLdohXW0GQR1XS
TURNVfBeIg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTN4LkC1NlEh|ryPMWXTRW5ITVJ?
REHMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\ZfmlEPTB;M{euPFIyOSEQvF2=NILZNGRUSU6JRWK=
EW-22NH3sdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\YTWM2OD12Mj6yPFg2KM7:TR?=M{HFcHNCVkeHUh?=
NCI-H446NYThSXB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnEfJdIUUN3ME20Nk44QDV|IN88US=>NXfle5BUW0GQR1XS
ES3M3jrSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTR|LkGzN|kh|ryPNVvLTpdpW0GQR1XS
EW-11NYfpXG52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\sS|FMUUN3ME20OE45OjF6IN88US=>NHjCTYxUSU6JRWK=
RH-1NWH6SIw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4HIOGlEPTB;NEeuOVgyOiEQvF2=M3X0RXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]
Features

Protocol(Only for Reference)

Kinase Assay:

[6]

Standard HDAC Assays Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.

Cell Assay:

[2]

Cell lines A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
Concentrations ~ 10 μM
Incubation Time 3 days
Method

Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.

Animal Study:

[1]

Animal Models A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
Formulation Dissolved with 0.05 N HCl, 0.1% Tween 80
Dosages 12.3, 24.5 and 49 mg/kg
Administration Administered orally once daily 5 days per week for 4 weeks

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Saito A, et al. Proc Natl Acad Sci U S A, 1999, 96(8), 4592-4597.

[2] Sugawara T, et al. 95th AACR, Orlando, 2004, Abst#2451

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02780804 Not yet recruiting Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplas  ...more Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm National Cancer Institute (NCI) March 2017 Phase 1
NCT02833155 Not yet recruiting Breast Cancer EddingPharm Oncology Co., LTD. July 2016 Phase 1
NCT02820961 Recruiting Breast Cancer|Estrogen Receptor Positive Breast Cancer Syndax Pharmaceuticals June 2016 Phase 1
NCT02697630 Not yet recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax P  ...more Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals June 2016 Phase 2
NCT02708680 Not yet recruiting Breast Cancer Syndax Pharmaceuticals|Roche Pharma AG April 2016 Phase 1|Phase 2

view more

Chemical Information

Download Entinostat (MS-275) SDF
Molecular Weight (MW) 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms SNDX-275
Solubility (25°C) * In vitro DMSO 75 mg/mL (199.25 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300 10mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name pyridin-3-ylmethyl 4-((2-aminophenyl)carbamoyl)benzylcarbamate

Frequently Asked Questions

  • Question 1
    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

    Answer: 2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related HDAC Products

  • LMK-235

    LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.

  • CAY10603

    CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.

  • 4SC-202

    4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.

  • Panobinostat (LBH589)

    Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

  • Vorinostat (SAHA, MK0683)

    Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

  • Trichostatin A (TSA)

    Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

    Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.

  • RGFP966

    RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.

  • Tubastatin A

    Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).

  • Mocetinostat (MGCD0103)

    Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Recently Viewed Items

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us